Get started

Financials · WGS

GeneDx Holdings Corp. (WGS) financials

For the twelve months ended Jun 30, 2026, GeneDx Holdings Corp. reported $454.43M of revenue and -$106.36M of net income.

Revenue, TTM
$454.43M
Revenue growth, YoY
+25.4%
Net income, TTM
-$106.36M
Net margin
-23.4%
Free cash flow, TTM
-$75.80M
EPS, diluted, TTM
-$3.62
Cash
$60.32M
Total debt
$96.84M
P/S
4.09
Market cap
$1.86B
Annual revenue$427.54M
FY2019FY2025
Annual net income-$21.02M
FY2019FY2025
Annual free cash flow$14.26M
FY2019FY2025

WGS revenue and earnings growth

WGS revenueQ2 2026$114.44M

Quarter YoY
+11.4%
QoQ
+11.9%
FY YoY
+40.0%
5Y CAGR
+19.0%

WGS revenue was $114.44M in fiscal Q2 2026 (ended Jun 30, 2026), up 11.4% from a year earlier and up 11.9% from the prior quarter. For the full fiscal 2025 it was $427.54M, up 40.0% from fiscal 2024. Compound annual growth was +19.0% over 5 years. It rose in 4 of the last 6 fiscal years. Fiscal 2025 is the highest of the 7 fiscal years on file.

WGS net incomeQ2 2026-$17.74M

WGS net income was -$17.74M in fiscal Q2 2026 (ended Jun 30, 2026), compared with $10.81M a year earlier. For the full fiscal 2025 it was -$21.02M, compared with -$52.29M in fiscal 2024.

WGS EPSQ2 2026-$0.60

WGS diluted EPS was -$0.60 in fiscal Q2 2026 (ended Jun 30, 2026), compared with $0.36 a year earlier. For the full fiscal 2025 it was -$0.73, compared with -$1.94 in fiscal 2024.

WGS free cash flowQ2 2026-$39.09M

WGS free cash flow was -$39.09M in fiscal Q2 2026 (ended Jun 30, 2026), compared with $8.05M a year earlier. For the full fiscal 2025 it was $14.26M, compared with -$33.99M in fiscal 2024. Fiscal 2025 is the highest of the 7 fiscal years on file.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Revenue$427.54M$305.45M$202.57M$234.69M$212.19M$179.32M$196.17M
Cost of revenue$129.37M$111.05M$112.56M$261.44M$228.80M$175.30M$113.39M
Gross profit$298.17M$194.40M$90.01M-$26.75M-$16.60M$4.03M$82.78M
Research and development$72.03M$45.72M$58.27M$86.20M$105.16M$72.70M$34.91M
Selling, general and admin$150.82M$104.52M$139.02M$216.17M$205.99M$100.74M$29.48M
Operating income-$13.08M-$23.21M-$180.60M-$667.65M-$446.15M-$241.99M-$30.41M
Interest expense---$3.21M$2.83M$2.47M$783.0K
Pre-tax income-$21.14M-$52.63M-$176.69M-$598.03M-$245.39M-$241.34M-$29.70M
Income tax-$116.0K-$343.0K-$926.0K-$49.05M$0$0$0
Net income-$21.02M-$52.29M-$175.77M-$548.98M-$245.39M-$241.34M-$29.70M
EPS, basic-$0.73-$1.94-$7.23-$53.63-$74.91-$1552188.00-$8713848.00
EPS, diluted-$0.73-$1.94-$7.23-$53.63-$74.91-$1552188.00-$8713848.00
Diluted shares28.6M26.9M24.3M10.2M3.3M155.4853.758

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Cash and equivalents$105.00M$86.20M$100.67M$138.30M$401.47M$108.13M$115.01M
Short-term investments$66.28M$55.97M$30.47M$0---
Receivables$74.37M$37.63M-$42.63M$26.51M$32.04M-
Inventory$13.95M$10.65M$8.78M$13.66M$33.46M$24.96M-
Current assets$268.29M$197.97M$182.34M$212.62M$483.54M$174.11M-
Goodwill$13.52M$0--$0$0-
Total assets$523.71M$419.38M$418.76M$490.94M$554.09M$251.64M-
Current liabilities$108.91M$54.82M$58.82M$144.30M$101.28M$73.44M-
Short-term debt$4.54M$1.21M$497.0K$4.75M$0$1.77M-
Long-term debt$48.18M$51.91M$52.69M$6.25M$11.00M$18.97M-
Total debt$52.72M$53.12M$53.19M$11.00M$11.00M$20.74M-
Total liabilities$215.53M$174.13M$190.74M$237.24M$165.99M$247.25M-
Shareholders' equity$308.18M$245.25M$228.02M$253.71M$388.10M-$330.05M-$88.71M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Operating cash flow$33.28M-$28.50M-$180.15M-$319.15M-$190.43M-$93.13M-$18.73M
Capital expenditures$19.02M$5.49M$5.25M$7.16M$9.40M$24.09M$11.92M
Free cash flow$14.26M-$33.99M-$185.40M-$326.31M-$199.83M-$117.22M-$30.65M
Investing cash flow-$61.52M-$30.13M-$43.73M-$141.33M-$20.79M-$31.97M-$15.46M
Financing cash flow$48.02M$44.16M$186.24M$197.31M$493.73M$129.06M$148.01M
Stock-based compensation$32.16M$9.14M-$326.0K$41.98M$219.42M$120.23M$5.48M
Depreciation and amortization$9.60M$7.90M$19.70M$50.00M$21.81M$11.73M$6.41M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Revenue growth, YoY40.0%50.8%-13.7%10.6%18.3%-8.6%-
Gross margin69.7%63.6%44.4%-11.4%-7.8%2.2%42.2%
Operating margin-3.1%-7.6%-89.2%-284.5%-210.3%-134.9%-15.5%
Net margin-4.9%-17.1%-86.8%-233.9%-115.6%-134.6%-15.1%
Free cash flow margin3.3%-11.1%-91.5%-139.0%-94.2%-65.4%-15.6%
Return on equity-6.8%-21.3%-77.1%-216.4%-63.2%--
Return on assets-4.0%-12.5%-42.0%-111.8%-44.3%-95.9%-
Current ratio2.463.613.101.474.772.37-
Debt to equity0.170.220.230.040.03--

Source: XBRL data GeneDx Holdings Corp. files with the SEC, latest filing dated Aug 3, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-33, first reported May 9, 2023.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

WGS peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
WGS$454.43M+25.4%-$106.36M-23.4%$1.86B
BTSG$15.25B+26.0%$410.27M2.7%$13.36B
CHE$2.66B+5.2%$282.40M10.6%$6.87B
HIMS$2.58B+28.0%-$142.03M-5.5%$6.06B
LFST$1.68B+22.6%$71.91M4.3%$5.26B
OPCH$5.75B+4.0%$215.19M3.7%$4.74B
PRVA$2.43B+19.2%$36.08M1.5%$3.12B
AVAH$2.60B+19.5%$274.76M10.6%$2.89B
ADUS$1.50B+11.5%$111.05M7.4%$2.32B

WGS FAQ

9 questions
  • What is WGS revenue?
    GeneDx Holdings Corp. (WGS) reported $454.43M of revenue for the twelve months ended Jun 30, 2026. That is up 25.4% from the year before. Revenue for fiscal 2025 was $427.54M.
  • Is WGS profitable?
    No. GeneDx Holdings Corp. reported a net loss of $106.36M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does WGS have?
    GeneDx Holdings Corp. reported $60.32M in cash and cash equivalents and $96.84M of debt on its most recent balance sheet in SEC filings.
  • How fast is WGS revenue growing?
    GeneDx Holdings Corp.'s revenue changed +40.0% in fiscal 2025, to $427.54M. Its compound annual growth rate was +19.0% over 5 years.
  • What is WGS gross margin?
    GeneDx Holdings Corp.'s gross profit was $315.24M on $454.43M of revenue for the twelve months ended Jun 30, 2026, a gross margin of 69.4%.
  • What is WGS free cash flow?
    GeneDx Holdings Corp. generated -$75.80M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$48.71M less capital expenditures.
  • What is WGS earnings per share?
    Diluted earnings per share were -$3.62 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did WGS last report financial results?
    The latest statements here come from GeneDx Holdings Corp.'s 10-Q filed on Aug 3, 2026, covering the period ended Jun 30, 2026.
  • Where does this WGS financial data come from?
    Quantisnow builds these statements from the structured XBRL data GeneDx Holdings Corp. files with the SEC. It is provided for information only and is not investment advice.